Drug Target Review – Issue 3 2021

Posted: 22 September 2021 | | No comments yet

In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies. 

DTR Issue 3 2021

Included in this issue:

    An integrated vaccination approach to neurodegeneration

    Dr Andrea Pfeifer, AC Immune
    Using brain models of patient-specific Alzheimer’s insights
    Victoria Rees, Drug Target Review
    The diversity of synthetic biology applications
    Dr Jim Collins, MIT and Wyss Institute at Harvard University
    High-throughput 3D cell migration assays in organ-on-a-chip technologies
    Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek, MIMETAS
    An IgM antibody platform to tackle SARS‑CoV-2 and its variants
    Dr Steve Carroll, IGM Biosciences
    Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
    Dr Chetan Karyekar, Janssen
    Improving drug discovery with advanced targeted proteomic monitoring workflows
    Professor Forest White, MIT
    Dr Lauren Stopfer, BioNTech

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here